Trial · NCT00892177
Results by group41
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 41
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) | Phase I : Dose Level 0 | 0 | participants who developed DLTs | ||
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) | Phase I : Dose Level 1 | 0 | participants who developed DLTs | ||
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) | Phase I : Dose Level 2 | 0 | participants who developed DLTs | ||
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) | Phase I : Dose Level 3 Cohort 1 | 0 | participants who developed DLTs | ||
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) | Phase I: Dose Level 3 Cohort 2 | 1 | participants who developed DLTs | ||
| Progression-free Survival at 6 Months (PFS6) (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | 0.29 | 90% Confidence Interval 0.19 to 0.39 | proportion of participants | |
| Progression-free Survival at 6 Months (PFS6) (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | 0.18 | 90% Confidence Interval 0.08 to 0.34 | proportion of participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | Grade 3 Adverse Event | 42 | participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | Grade 3 Adverse Event | 23 | participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | Grade 4 Adverse Event | 8 | participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | Grade 4 Adverse Event | 2 | participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | Grade 5 Adverse Event | 5 | participants | |
| Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | Grade 5 Adverse Event | 3 | participants | |
| Overall Survival (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | 7.3 | 95% Confidence Interval 6.2 to 8.7 | months | |
| Overall Survival (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | 7.9 | 95% Confidence Interval 6.6 to 11.3 | months | |
| Time-to-disease Progression (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | 3.3 | 95% Confidence Interval 2.79 to 4.6 | months | |
| Time-to-disease Progression (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | 3.5 | 95% Confidence Interval 2.83 to 4.6 | months | |
| Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | Cycle 0 | 139.5 | Standard Deviation 26.2 | units on a scale |
| Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II) | Phase II: Arm B (Bevacizumab + Placebo) | Cycle 0 | 138.3 | Standard Deviation 22.4 | units on a scale |
| Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II) | Phase II: Arm A (Bevacizumab + Dasatinib) | Cycle 2 | 131.2 | Standard Deviation 27.9 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00892177/results